In Q3 2024, Pfizer's oncology business grew by 31% year-on-year, ranking third among U.S. biopharmaceutical companies in oncology revenue for the first half of the year. Among oncology products, the PARP inhibitor Talzenna saw a year-on-year increase of 77%, while the BCMAxCD3 bispecific antibody Elrexfio grew 80% quarter-on-quarter, showing rapid growth.

Urogenital tumors are currently a key focus area for Pfizer. The androgen receptor signaling inhibitor Xtandi (enzalutamide, +28%) and the Nectin-4 ADC drug Padcev (sacituzumab govitecan, acquired from Seagen) brought in revenues of $506 million and $409 million, respectively, ranking second and third in Pfizer's oncology drug sales. The top seller was the CDK4/6 inhibitor Ibrance (palbociclib), with Q3 sales of $1.087 billion, a year-on-year decrease of 12%.

Additionally, the third-generation ALK inhibitor Lorbrena (lorlatinib) generated $206 million in revenue, a year-on-year increase of 31%. The BRAF/MEK inhibitor combination Braftovi/Mektovi brought in $173 million, a year-on-year increase of 32%. In December 2023, Pfizer acquired Seagen for $43 billion, gaining four ADC drugs. In addition to Padcev mentioned above, these include the CD30-targeting Adcetris (brentuximab vedotin), HER2-targeting Tukysa (tucatinib), and tissue factor (TF)-targeting Tivdak. In Q3 2024, these four ADC drugs from Seagen contributed $854 million in revenue to Pfizer.

The anticoagulant Eliquis generated sales of $1.617 billion, a year-on-year increase of 9%. This product's growth in certain U.S. and European markets due to increased market share for non-valvular atrial fibrillation somewhat offset the impact of generic competition in some international markets.

Revenue from rare disease treatments (Vyndaqel, Vyndamax, Vynmac) was $1.447 billion, a year-on-year increase of 63%, mainly driven by strong demand in the U.S. and developed international markets. The headache medication Nurtec ODT (rimegepant) had sales of $337 million, a year-on-year increase of 45%, with total prescriptions growing by 28%, maintaining its leading position among oral CGRP drugs.

The Prevnar family (Prevnar 20 & 13) generated sales of $1.803 billion, a year-on-year increase of 2%. Prevnar 20 has achieved 83% and 97% market share in pediatrics and adults, respectively. Following last week's recommendation from the Advisory Committee on Immunization Practices (ACIP) to expand adult pneumococcal vaccination to all adults aged 50 and above, Prevnar 20 will further serve more populations. 

The RSV vaccine Abrysvo generated sales of $356 million, with its market share exceeding 50% among retailers and clinics outside of wholesalers, and its retail market share has grown for nine consecutive weeks, currently reaching 43%. Recently, the FDA approved Abrysvo for patients aged 18 to 59 at increased risk for RSV-related lower respiratory tract disease, further expanding the vaccine's eligible population.

Paxlovid generated $2.703 billion in revenue, which exceeded Pfizer's expectations, reflecting an increase of nearly $2.5 billion compared to Q3 last year. Comirnaty's revenue was $1.422 billion, a year-on-year increase of 9%.

Pfizer's Q3 product pipeline made notable progress, whether in regulatory approvals, Phase III clinical result readouts, or key project launches. As shown in the image above, most projects are progressing smoothly as planned; however, the Phase III clinical study of the gene therapy Fordadistrogene Movaparvovec for the treatment of Duchenne muscular dystrophy did not meet its primary endpoint. Additionally, the Phase III clinical study for mRNA Covid/Flu did not achieve all primary endpoints.